via MedicalXpress
Korean researchers have screened 48 FDA-approved drugs against SARS-CoV-2, and found that 2, which are already FDA-approved for other illnesses, seem promising.
The FDA approval for other uses would greatly reduce the time needed to gain FDA approval of use in COVID-19. The research is published in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology.
The investigators tested the drugs in Vero cells, a cell line developed from kidney cells of the African Green Monkey, which are commonly used to grow viruses for vaccine production.
An anti-helminthic drug called niclosamide demonstrated “very potent” antiviral activity against SARS-CoV-2, according to coauthors Sangeun Jeon, Meehyun Ko, and their collaborators, of the Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, Korea. “Not surprisingly, its broad-spectrum antiviral effect has been well documented in the literature, including antiviral properties against SARS- and MERS-CoV,” they write.
A downside of niclosamide is low absorption, which undercuts the drug’s power by reducing the dose that reaches the target tissue. However, “Further development or drug formulation could enable effective delivery of this drug to the target tissue,” according to the report.
Despite substantially lower antiviral potency, ciclesonide, an inhaled corticosteroid used to treat asthma and allergic rhinitis, also showed promise against SARS-CoV-2. Intriguingly, the investigators note that a study published earlier this year ( by Matsuyama et al.) a treatment report of 3 patients infected by SARS-CoV-2, demonstrated antiviral activity and revealed the drug’s molecular target to be a viral protein called Nsp15.
“With its proven anti-inflammatory activity, ciclesonide may represent as a potent drug which can manifest [the] dual roles [of antiviral and anti-inflammatory] for the control of SARS-CoV-2 infection,” the investigators conclude. The anti-inflammatory activity might play a critical role in dampening or preventing the cytokine storms, an immune inflammatory overreaction that can kill COVID-19 patients.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
SARS-CoV-2
- New COVID-19 ‘FLiRT’ Variants Identified—What You Need to Know
A new group of COVID variants, dubbed "FLiRT," have arrived and are surging to dominance in the United States. Here, experts break down whether you can expect a COVID wave this summer.
- Data suggest SARS-CoV-2 could jump from raccoon dogs to people, but species barrier may interfere
The Global Polio Eradication Initiative confirmed two new polio cases this week, both caused by circulating vaccine-derived poliovirus type 2. Angola has its first polio case since 2022. Chad reported ...
- "FLiRT" COVID variants are now more than a third of U.S. cases. Scientists share what we know about them so far.
More than a third of COVID-19 cases in the U.S. are now estimated to be from a new, fast-growing member of a group of so-called "FLiRT" variants, nicknamed for their small but distinctive changes ...
- Experts blast CDC over refusal to test sewage for signs of H5N1 bird flu virus
As officials attempt to determine the extent of bird flu outbreaks among dairy herds, some experts are urging that wastewater surveillance begin immediately.
- New FLiRT variants of SARS-Cov-2 spreading in US
Health authorities in the United States are warning about the latest version of Covid-19 with the appearance of the so-called FLiRT variations, which represent the new version of the SARS-CoV-2 virus, ...
Go deeper with Google Headlines on:
SARS-CoV-2
[google_news title=”” keyword=”SARS-CoV-2″ num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Covid-19
- Pregnant mom, 31, gets COVID-19 and rare fungal infection but recovers: ‘Not medically possible’
Pregnant mom caught COVID-19 and developed mucormycosis, a rare, often fatal fungal infection. Patients normally need surgery to treat it. But somehow she survived.
- Southern California man found guilty of soliciting investors for bogus COVID-19 cure
A man from Orange County has been found guilty of soliciting investors for a bogus COVID-19 cure. The US Department of Justice says 56-year-old Keith Lawrence Middlebrook of Huntington Beach was convicted of 11 counts of wire fraud.
- After fall in demand for COVID-19 tests, San Diego’s QuidelOrtho to lay off 500 workers
QuidelOrtho's new CEO started this week and joined investors during the local diagnostic company's first-quarter earnings call
- AstraZeneca withdraws Covid-19 vaccine, citing low demand
AstraZeneca is withdrawing its highly successful coronavirus vaccine, citing the availability of a plethora of new shots that has led to a decline in demand.
Go deeper with Google Headlines on:
Covid-19
[google_news title=”” keyword=”Covid-19″ num_posts=”5″ blurb_length=”0″ show_thumb=”left”]